We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

48 hedge funds and large institutions have $77.2M invested in Regulus Therapeutics in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

244% more capital invested

Capital invested by funds: $22.4M → $77.2M (+$54.8M)

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

4% more funds holding

Funds holding: 46 → 48 (+2)

0.14% more ownership

Funds ownership: 0.36% → 0.5% (+0.14%)

Holders
48
Holders Change
+2
Holders Change %
+4.35%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
18
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NMC
NEA Management Company
Maryland
+$11.5M
2
BI
BVF Inc
California
+$10.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.96M
4
BC
Broadfin Capital
New York
+$4.5M
5
BC
Boxer Capital
California
+$2.3M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$363K
2
ARTA
A.R.T. Advisors
New York
-$246K
3
Wells Fargo
Wells Fargo
California
-$216K
4
LP
LMR Partners
United Kingdom
-$164K
5
PP
Paloma Partners
Connecticut
-$144K
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
26
Creative Planning
Kansas
$51K +$42K +334 +4,175%
BCM
27
Bourgeon Capital Management
Connecticut
$51K +$42.8K +340 New
Mariner
28
Mariner
Kansas
$47K – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$43K +$10.2K +81 +40%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$37K +$31.2K +248 New
GC
31
Guggenheim Capital
Illinois
$36K +$30.4K +242 New
State Street
32
State Street
Massachusetts
$34K -$6.79K -54 -20%
ARTA
33
A.R.T. Advisors
New York
$31K -$246K -1,955 -90%
FIM
34
Freedom Investment Management
Connecticut
$30K +$25.3K +201 New
Macquarie Group
35
Macquarie Group
Australia
$25K – – –
HighTower Advisors
36
HighTower Advisors
Illinois
$25K +$10.6K +84 +99%
IA
37
IFP Advisors
Florida
$19K – – –
BCM
38
Brookstone Capital Management
Illinois
$16K +$13.8K +110 New
DY
39
Dowling & Yahnke
California
$14K – – –
LTFS
40
Ladenburg Thalmann Financial Services
Florida
$12K -$503 -4 -5%
JP Morgan Chase
41
JP Morgan Chase
New York
$10K -$9.68K -77 -55%
Morgan Stanley
42
Morgan Stanley
New York
$7K -$67.4K -536 -92%
MAM
43
Meeder Asset Management
Ohio
$5K +$3.02K +24 +200%
Bank of America
44
Bank of America
North Carolina
$5K +$3.9K +31 +1,550%
Simplex Trading
45
Simplex Trading
Illinois
$1K +$880 +7 +350%
SIM
46
Sonora Investment Management
Arizona
$250 – – –
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$5 – – –
Goldman Sachs
48
Goldman Sachs
New York
– -$363K -3,069 Closed
LP
49
LMR Partners
United Kingdom
– -$164K -1,386 Closed
PP
50
Paloma Partners
Connecticut
– -$144K -1,217 Closed
1
2
3

RGLS Hedge Fund Activity: Q3 2017 in Review

48 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2017, worth a combined $77.2M — up 244% from $22.4M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RGLS positions and 8 closed out — a net gain of 3 holders — while 18 added to existing stakes and 13 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $11.5M. The largest seller was Goldman Sachs, exiting entirely with an estimated $363K sold.

  • 48 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2017, up from 46 in Q2 2017.
  • Funds reported $77.2M of Regulus Therapeutics stock for Q3 2017, up 244% quarter-over-quarter.
  • 11 funds opened new Regulus Therapeutics positions in Q3 2017 and 8 closed out, a net change of +3 holders.
  • The largest Regulus Therapeutics buyer in Q3 2017 was NEA Management Company, an estimated $11.5M added.
  • The largest Regulus Therapeutics seller in Q3 2017 was Goldman Sachs, an estimated $363K sold.

Based on aggregated 13F filings for Q3 2017.